<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>52-ORAL-ANTICOAGULANTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ORAL ANTICOAGULANTS" code="B01A-001" /></DRUG1>
<DRUG2>
<CLASS name="OTHER ORAL ANTICOAGULANTS" code="B01A-001" /></DRUG2>
<DESCRIPTION>Risk of increase of hemorrhagic events when one oral anticoagulant is replaced with another.</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
<COMMENT></COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>52-ORAL-ANTICOAGULANTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ORAL ANTICOAGULANTS" code="B01A-001" /></DRUG1>
<DRUG2>
<DRUG name="ACETYLSALICYLIC ACID" rxcui="1191">
<ATC code="A01AD05" />
<ATC code="B01AC06" />
<ATC code="N02BA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the risk of hemorrhage, especially in cases with a previous gastroduodenal ulcer

</DESCRIPTION>
<SEVERITY>Contraindication with:</SEVERITY>
<COMMENT></COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>52-ORAL-ANTICOAGULANTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ORAL ANTICOAGULANTS" code="B01A-001" /></DRUG1>
<DRUG2>
<CLASS name="PLATELET AGGREGATION INHIBITORS" code="B01AC-001" /></DRUG2>
<DESCRIPTION>Increase of the risk of hemorrhage

</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>52-ORAL-ANTICOAGULANTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ORAL ANTICOAGULANTS" code="B01A-001" /></DRUG1>
<DRUG2>
<CLASS name="NON STEROIDAL ANTI-INFLAMMATORY DRUGS" code="M01A-002" /></DRUG2>
<DESCRIPTION>Increase of the oral anticoagulant&#39;s risk of hemorrhage (irritation of the gastroduodenal mucosa by the non-steroidal anti-inflammatories)

</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT></COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>52-ORAL-ANTICOAGULANTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ORAL ANTICOAGULANTS" code="B01A-001" /></DRUG1>
<DRUG2>
<DRUG name="DEFIBROTIDE" rxcui="1311089">
<ATC code="B01AX01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of hemorrhage</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>52-ORAL-ANTICOAGULANTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ORAL ANTICOAGULANTS" code="B01A-001" /></DRUG1>
<DRUG2>
<CLASS name="GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)" code="A0-H0-001" /></DRUG2>
<DESCRIPTION>Glucocorticoids (general and rectal routes): possible impact of the corticotherapy on the metabolism of the vitamin K antagonist and on that of the factors of coagulation. Risk of hemorrhage specific to the corticotherapy (digestive mucosa, vascular fragility) with large doses or in treatment prolonged beyond 10 days. </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT></COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>52-ORAL-ANTICOAGULANTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ORAL ANTICOAGULANTS" code="B01A-001" /></DRUG1>
<DRUG2>
<CLASS name="LOW MOLECULAR WEIGHT HEPARINS AND RELATED DRUGS (CURATIVE DOSES AND/OR OLDER PATIENT)" code="B01AB-001" /></DRUG2>
<DESCRIPTION>Increase of the risk of hemorrhage

</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT></COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>52-ORAL-ANTICOAGULANTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ORAL ANTICOAGULANTS" code="B01A-001" /></DRUG1>
<DRUG2>
<CLASS name="SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)" code="N06AB" /></DRUG2>
<DESCRIPTION>Increase of the risk of hemorrhage

</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT></COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>52-ORAL-ANTICOAGULANTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ORAL ANTICOAGULANTS" code="B01A-001" /></DRUG1>
<DRUG2>
<DRUG name="IPILIMUMAB " rxcui="1094833">
<ATC code="L01XC11" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the risk of digestive system hemorrhage</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT></COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>52-ORAL-ANTICOAGULANTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ORAL ANTICOAGULANTS" code="B01A-001" /></DRUG1>
<DRUG2>
<CLASS name="MIXED ADRENERGIC-SEROTONINERGIC MEDICATIONS" code="N06A" /></DRUG2>
<DESCRIPTION>Increase of the risk of hermorrhage.</DESCRIPTION>
<SEVERITY>Precaution for use </SEVERITY>
<COMMENT></COMMENT>
</INTERACTION>
</INTERACTIONS>
